Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $265.32, for a total value of $53,064.00. Following the completion of the sale, the director now owns 8,080 shares in the company, valued at $2,143,785.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Teleflex Incorporated (NYSE TFX) traded down $1.65 on Thursday, reaching $250.10. The company had a trading volume of 377,300 shares, compared to its average volume of 261,304. Teleflex Incorporated has a fifty-two week low of $151.22 and a fifty-two week high of $271.23. The company has a market capitalization of $11,341.15, a price-to-earnings ratio of 31.12, a PEG ratio of 2.15 and a beta of 1.09. The company has a quick ratio of 3.70, a current ratio of 4.72 and a debt-to-equity ratio of 0.88.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The business had revenue of $534.70 million for the quarter, compared to analyst estimates of $522.94 million. During the same quarter in the prior year, the company posted $1.80 earnings per share. Teleflex’s revenue was up 17.3% on a year-over-year basis. equities research analysts anticipate that Teleflex Incorporated will post 8.35 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Wednesday, November 15th will be issued a dividend of $0.34 per share. The ex-dividend date is Tuesday, November 14th. This represents a $1.36 annualized dividend and a yield of 0.54%. Teleflex’s payout ratio is presently 24.82%.

TFX has been the topic of a number of research reports. Jefferies Group restated a “buy” rating and issued a $253.00 price target (up from $230.00) on shares of Teleflex in a report on Wednesday, August 9th. Deutsche Bank restated a “buy” rating and issued a $238.00 price target (up from $220.00) on shares of Teleflex in a report on Wednesday, August 9th. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a report on Thursday, August 24th. Needham & Company LLC boosted their price target on Teleflex from $228.00 to $237.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. Finally, KeyCorp restated a “hold” rating on shares of Teleflex in a report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $274.44.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atlanta Capital Management Co. L L C raised its holdings in Teleflex by 2.6% during the second quarter. Atlanta Capital Management Co. L L C now owns 2,519,464 shares of the medical technology company’s stock worth $523,444,000 after acquiring an additional 64,985 shares in the last quarter. Janus Henderson Group PLC raised its stake in Teleflex by 50,429.2% in the second quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock valued at $377,296,000 after buying an additional 1,812,426 shares during the period. State Street Corp raised its stake in Teleflex by 1.8% in the second quarter. State Street Corp now owns 1,399,922 shares of the medical technology company’s stock valued at $290,853,000 after buying an additional 25,401 shares during the period. American Century Companies Inc. raised its stake in Teleflex by 41.6% in the third quarter. American Century Companies Inc. now owns 1,187,909 shares of the medical technology company’s stock valued at $287,438,000 after buying an additional 348,829 shares during the period. Finally, Koch Industries Inc. raised its stake in Teleflex by 47,174.3% in the second quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock valued at $955,000 after buying an additional 957,639 shares during the period. Institutional investors and hedge funds own 89.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/teleflex-incorporated-tfx-director-sells-53064-00-in-stock/1750183.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.